Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Predatory bacterium offers hope in superbug fight
zebrafish
"The zebrafish has been a fantastic model for us to generate rapid understanding of how a living antibiotic can work in an animal."

Nature offers therapy for MDR Shigella infections

For the first time, a naturally occurring predatory bacterium has been used to clear multi-drug-resistant (MDR) Shigella infections. Scientists say the discovery is an important step in the fight against superbugs.

Shigella is a common cause of 'traveller's diarrhoea' and causes more than 160 million illnesses and one million deaths each year. Drug-resistant Shigella is on the rise as, although it is usually self-limiting, antibiotics are often used even in mild cases to clear up the symptoms more quickly.

Researchers from Imperial College London and the University of Nottingham believe they have found a creative solution in the natural environment.

Zebrafish larvae were injected with a lethal dose of Shigella flexneri M90T, a strain that is resistant to streptomycin and carbenicillin antibiotics. The predatory bacterium, Bdellovibrio bacteriovorus, was then injected into the larvae's infection site.

The team observed a decrease in the number of Shigella seen. However, without Bdellovibrio, the zebrafish were unable to control the replication of Shigella and the level of bacteria rose.

Bdellovibrio is also able to reduce the pathogen load in immunocompromised zebrafish larvae that are depleted of white blood cells. But survival rates are significantly higher in those that are immune-competent. Researchers say this demonstrates that Bdellovibrio's maximum benefit comes from its ability to work with the host's immune system.

Dr Michael Chew, science portfolio advisor at Wellcome, which provided funding for the study, commented: "It may be unusual to use a bacterium to get rid of another, but in the light of the looming threat from drug resistant infections the potential of beneficial bacteria-animal interactions should not be overlooked.

"We are increasingly relying on last line antibiotics, and this innovative study demonstrates how predatory bacteria could be an important additional tool to drugs in the fight against resistance."

Co-lead authors Dr Serge Mostowy and Dr Alex Willis added: "The urgent requirement for new antimicrobials calls for increasingly creative solutions. The zebrafish has been a fantastic model for us to generate rapid understanding of how a living antibiotic can work in an animal.

"Our findings here provide the basis for testing Bdellovibrio in higher vertebrates and ultimately, humans."

Image by Lynn Ketchum, courtesy of Oregon State University/CC BY-SA 2.0

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.